H.C. Wainwright bullish on Insmed into Tuesday’s FDA panel

H.C. Wainwright analyst Andrew Fein is bullish on shares of Insmed into Tuesday’s FDA panel meeting. The collective strength of the Amikacin Liposome Inhalation Suspension data “essentially removes the regulatory risks,” Fein tells investors in a research note. With no effective treatment available, the analyst expects a positive panel vote. He reiterates a Buy rating on Insmed with a $35 price target. The analyst adds that if he were to assume a 100% probability of success for ALIS, he “could easily justify” a valuation north of $50 per share.

https://bit.ly/2Oau0qC